Perrigo second quarter sales rise 10% to $221.7 mil., net income up 13%.
This article was originally published in The Tan Sheet
PERRIGO SALES RISE 10% TO $221.7 MIL. IN SECOND QUARTER on double-digit sales increases in the company's OTC and nutritional businesses. The private label firm said the gain in OTC sales reflected a severe cough, cold and flu season through the end of the second quarter (ended Dec. 31) that contributed to higher sales in the cough/cold and analgesic categories
You may also be interested in...
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.